| ²é¿´: 338 | »Ø¸´: 0 | ||
ÕÅÏÖÄþгæ (³õÈëÎÄ̳)
|
[ÇóÖú]
ÇóÕâ¶ÎÓ¢ÎĵķÒë
|
|
Unsupervised clustering of mutations and data from RNA, DNA-copy-number, and DNA-methylation platforms uncovered concordant classification of three robust, nonoverlapping, prognostically significant subtypes of lower-grade glioma that were captured more accurately by IDH, 1p/19q, and TP53 status than by histologic class. Patients who had lower-grade gliomas with an IDH mutation and 1p/19q codeletion had the most favorable clinical outcomes. Their gliomas harbored mutations in CIC, FUBP1, NOTCH1, and the TERT promoter. Nearly all lower-grade gliomas with IDH mutations and no 1p/19q codeletion had mutations in TP53 (94%) and ATRX inactivation (86%). The large majority of lower-grade gliomas without an IDH mutation had genomic aberrations and clinical behavior strikingly similar to those found in primary glioblastoma. |
» ²ÂÄãϲ»¶
270·ÖÇóµ÷¼Á
ÒѾÓÐ3È˻ظ´
²ÄÁϵ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁÏ0856 Ó¢Ò»Êý¶þ 323 Çóµ÷¼Á
ÒѾÓÐ13È˻ظ´
»¯Ñ§0703-Ò»Ö¾Ô¸211-338·ÖÇóµ÷¼Á
ÒѾÓÐ5È˻ظ´
µ÷¼Á
ÒѾÓÐ4È˻ظ´
Ò»Ö¾Ô¸±±½»´ó²ÄÁϹ¤³Ì×Ü·Ö358Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
Ò»Ö¾Ô¸ ½ÄÏ´óѧ 085602 »¯¹¤×¨Ë¶ 338·ÖÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
304Çóµ÷¼Á£¨085602£¬¹ýËļ¶£¬Ò»Ö¾Ô¸985£©
ÒѾÓÐ15È˻ظ´
¹¤¿ÆÇóµ÷¼Á
ÒѾÓÐ15È˻ظ´














»Ø¸´´ËÂ¥